- Apr 11, 2021
Magnostics is a biotechnology start-up based on technology developed through successive investments (€1.6MM) by NASA.
Magnostics manufactures enhanced performance magnetic nanoparticles as parts of kits and as a B2B supplier for major Diagnostics and Life Science manufacturers. Magnostics produces nanoparticles that are essential components for in vitro diagnostic (IVD), bioseparation and high throughput screening (HTS). Magnostics also manufactures reagents for ultra-sensitive point of care tests (POCT), currently under development.
The target markets, identified from both primary and secondary market research, include:
1. Laboratories doing viral extraction for detection using RT-qPRC, such as, SARS-CoV-2.
2. Developers of IVD kits need a faster, more responsive and cost-effective base material to manufacture point-of-care testing kits.
3. Manufacturers and distributors of Point of care testing (POCT) including those that are replacing colloidal gold with magnetic nanoparticles to increase sensitivity and speed.